Cannabis for Inflammatory Bowel Disease

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Nuoroda įrašoma į mainų sritį

Statusas

Rėmėjai

Meir Medical Center

KLINIKINIS TYRIMAS: NCT01040910

BioSeek: nct01040910

Raktažodžiai

Santrauka

Background: The marijuana plant Cannabis has been used for centuries in the medicinal treatment of many disorders and is still the subject of medical research and public debate. Cannabinoids have been purported to alleviate a variety of neurological conditions such as MS-related symptoms including spasticity, pain, tremor and bladder dysfunction. Other neurological conditions like chronic intractable pain, dystonic movement disorders and Tourette's Syndrome were all reported to be alleviated by cannabis use. Cannabis has been used to treat anorexia in AIDS and cancer patients. In gastroenterology cannabis has been used to treat symptoms and diseases including anorexia, emesis, abdominal pain, gastroenteritis, diarrhoea, intestinal inflammation and diabetic gastroparesis.

Cannabinoids have also a profound anti inflammatory effect, mainly through the CB2 receptor. Cell mediated immunity may be impaired in chronic marijuana users. And a potent anti-inflammatory effect of cannabis was observed in rats . Studying the functional roles of the endocannabinoid system in immune modulation reveals that there are no major immune events which do not involve the endocannabinoid system. Cannabinoids shift the balance of pro-inflammatory cytokines and anti-inflammatory cytokines towards the T-helper cell type 2 profiles (Th2 phenotype), and suppress cell-mediated immunity whereas humoral immunity may be enhanced. They are therefore used for various inflammatory conditions including rheumatoid arthritis and asthma. In a mouse model of colitis cannabinoids were found to ameliorate inflammation and there are many anecdotal reports about the effect of cannabis in inflammatory bowel disease. However, there are no methodical reports of the effect of cannabis on inflammatory bowel disease. The aim of the proposed study is to examine in a double blind placebo controlled fashion the effect of smoking cannabis on disease activity in patients with IBD.

Datos

Paskutinį kartą patikrinta:	11/30/2011
Pirmasis pateikimas:	12/28/2009
Numatytas registravimas pateiktas:	12/28/2009
Pirmas paskelbtas:	12/29/2009
Paskutinis atnaujinimas pateiktas:	12/14/2011
Paskutinis atnaujinimas paskelbtas:	12/15/2011
Faktinė studijų pradžios data:	12/31/2009
Numatoma pirminio užbaigimo data:	05/31/2012
Numatoma studijų užbaigimo data:	06/30/2012

Būklė ar liga

Crohn's Disease

Ulcerative Colitis

Intervencija / gydymas

Drug: cannabis smoking for IBD

Drug: patients smoking non active cannabis

Fazė

Fazė 1/Fazė 2

Rankų grupės

Ranka	Intervencija / gydymas
Active Comparator: cannabis smoking for IBD patients with active disease receiving active cannabis for smoking	Drug: cannabis smoking for IBD smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
Placebo Comparator: patients smoking non active cannabis patients with active disease receiving cannabis from which active ingredients have been chemically removed	Drug: patients smoking non active cannabis smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed

Tinkamumo kriterijai

Amžius, tinkami studijuoti	20 Years Į 20 Years
Tinkamos studijoms lytys	All
Priima sveikus savanorius	Taip
Kriterijai	Inclusion Criteria: 1. Patients with a diagnosis IBD at least 3 months before recruitment will be eligible to the study. 2. Patients with active disease who are resistant to either 5 ASA, steroids or immunomodulators, or who can not receive those drugs due to adverse reactions will be offered the possibility of smoking cannabis at a dose of two cigarettes a day which will contain either regular cannabis or pre treated cannabis as placebo. 3. Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo score above 3 in UC. 4. Age above 20. Exclusion Criteria: 1. Patients with a known mental disorder 2. Patients who are deemed to be at a high risk of abuse or addiction to the study drug. 3. Pregnant women 4. Patients who are sensitive to any of the ingredients of the study medication. 5. Patients who are unable to give informed consent. 6. Patients who may need surgery in the near future.

Rezultatas

Pirminės rezultatų priemonės

1. reduction of CDAI by 70 points [8 weeks]

Antrinės rezultatų priemonės

1. adverse events due to cannabis smoking [8 weeks]

2. change in quality of life before and at the end of study [8 weeks]

3. change in IL-10. IL-2. TGF beta [week 0 and week 8]

Cannabis for Inflammatory Bowel Disease

Raktažodžiai

anoreksija

cannabinoid

vėžys

abdominal pain

vėmimas

uždegimas

astma

gastroparesis

colitis

gastroenteritas

arthritis

tremor

kanapė

priešuždegiminis